Company intelligence / Profile preview

Mucosis B.V.

Groningen, Netherlands

Ownership: Private
Development stage: Other

Overview

Mucosis’s lead product SynGEM®, a stabilized recombinant intranasal vaccine against RSV, entered Phase I human proof-of-concept studies in 2016 at Imperial College London. The trial was supported by €3.4 million from the Wellcome Trust and involved 36 volunteers to assess antibody production. The company has also developed PneuGEM® (pneumococcus) and FluGEM® (influenza), with FluGEM® serving as a successful proof of concept in humans for the Mimopath platform[2][5]. No recent late-stage results are available.

Therapeutic areas: Infectious Diseases
Modalities: Needle-free vaccines (mucosal vaccines)recombinant subunit vaccinesbacterium-like particles (BLPs)
Industry: Biotech

Drug pipeline

1 asset

SynGEM

Partnerships

US National Institutes of Health (NIH)Changchun BCHT Biotechnology Co. (China)Utrecht UniversityNetherlands Enterprise Agency

Beyond the preview

Go deeper on Mucosis B.V..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucosis B.V..